Breaking Through Solid Tumors: GT Biopharma's B7-H3 Targeting Strategy Enters Human Testing

GT Biopharma has cleared a significant regulatory hurdle, receiving FDA greenlight to commence an investigational new drug (IND) application for GTB-5550, an NK cell-redirecting immunotherapy candidate aimed at B7-H3 expressing solid malignancies. This marks a pivotal step in the company’s push into one of oncology’s most intractable challenges.

Why B7-H3 Matters in Tumor Immunity

The landscape for solid tumor treatment remains constrained despite advances in checkpoint inhibitors and cell therapies. The global cancer therapeutics market, valued at approximately $362 billion, continues to search for breakthroughs in cancers like prostate, lung, breast, ovarian, and pancreatic disease. B7-H3, an immune checkpoint marker frequently upregulated across these tumor types, serves as an ideal target for redirecting the body’s natural killer cells—specialized immune assassins capable of recognizing and eliminating cancer cells without the genetic modification required by CAR-T approaches.

The TriKE Technology: A Tri-Specific Approach

GTB-5550 is engineered on GT Biopharma’s proprietary TriKE (tri-specific NK cell engager) platform, a technology designed to simultaneously activate and direct natural killer cells against tumor cells. The construct comprises three functional elements:

• A nanobody that engages the CD16 receptor on NK cells, triggering their cytotoxic machinery
• An IL-15 signaling component that sustains NK cell proliferation and survival in the tumor microenvironment
• A B7-H3-targeting nanobody that bridges NK cells to cancer cells expressing this immune escape marker

This dual-nanobody architecture represents the first GTB TriKE candidate eligible for subcutaneous dosing, potentially offering patients a less burdensome treatment regimen compared to intravenous infusion protocols.

Clinical Path Forward

The Phase 1 basket trial architecture, launching in 2026, will evaluate GTB-5550 across seven distinct cohorts of metastatic disease. The trial incorporates dose-escalation phases to identify tolerability boundaries, followed by expansion arms measuring safety profiles and preliminary efficacy signals. Key efficacy metrics include progression-free survival and overall survival assessments over a 12-month window. The subcutaneous administration route prioritizes patient convenience without compromising pharmacodynamic delivery.

De-Risking Through Parallel Program

GT Biopharma is simultaneously advancing GTB-3650 in myeloid malignancies, with Phase 1 data anticipated in the first half of 2026. Leadership has suggested that learnings from hematologic programs will inform GTB-5550’s solid tumor strategy, particularly given that B7-H3-driven solid tumors represent a patient population “orders of magnitude larger” than blood cancer indications.

Financial Runway and Market Position

As of December 31, 2025, GT Biopharma reported preliminary cash reserves of approximately $7 million, sufficient to fund operations into the third quarter of 2026. Over the preceding 12 months, GTBP equity has oscillated between $0.54 and $3.85. Current trading sits at $0.71, reflecting an 8.82% session gain. The company’s dual-program approach and B7-H3 targeting technology position it within a competitive cell therapy landscape as multiple players advance NK cell and checkpoint-targeting strategies.